ATE472333T1 - Rückfaltung von proteinen der transforming-growth-factor-beta-familie - Google Patents

Rückfaltung von proteinen der transforming-growth-factor-beta-familie

Info

Publication number: ATE472333T1
Authority: AT; Austria
Prior art keywords: growth factor; transforming growth; factor beta; refolding; family proteins
Prior art date: 2004-08-19

Application number

AT05789270T

Other languages

English (en)

Inventor

Anthony Rossomando

R Pepinsky

Banjian Gong

Original Assignee

Biogen Idec Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-08-19

Filing date

2005-08-18

Publication date

2010-07-15

2005-08-18 Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc

2010-07-15 Application granted granted Critical

2010-07-15 Publication of ATE472333T1 publication Critical patent/ATE472333T1/de

Links

108090000623 proteins and genes Proteins 0.000 title abstract 3
102000004169 proteins and genes Human genes 0.000 title abstract 3
102000004887 Transforming Growth Factor beta Human genes 0.000 title abstract 2
108090001012 Transforming Growth Factor beta Proteins 0.000 title abstract 2
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title abstract 2
239000000203 mixture Substances 0.000 abstract 2

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Zoology (AREA)
Medicinal Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Biophysics (AREA)
Toxicology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Wood Science & Technology (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Engineering & Computer Science (AREA)
Epidemiology (AREA)
Immunology (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

AT05789270T 2004-08-19 2005-08-18 Rückfaltung von proteinen der transforming-growth-factor-beta-familie ATE472333T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US60282504P	2004-08-19	2004-08-19
PCT/US2005/029638 WO2006023782A2 (en)	2004-08-19	2005-08-18	Refolding transforming growth factor beta family proteins

Publications (1)

Publication Number	Publication Date
ATE472333T1 true ATE472333T1 (de)	2010-07-15

Family

ID=35968236

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05789270T ATE472333T1 (de)	2004-08-19	2005-08-18	Rückfaltung von proteinen der transforming-growth-factor-beta-familie

Country Status (15)

Country	Link
US (2)	US8722862B2 (de)
EP (1)	EP1784203B1 (de)
JP (1)	JP4959566B2 (de)
KR (1)	KR101241551B1 (de)
CN (2)	CN101043899B (de)
AT (1)	ATE472333T1 (de)
AU (1)	AU2005277227B2 (de)
BR (1)	BRPI0514409A (de)
CA (1)	CA2577690C (de)
DE (1)	DE602005022082D1 (de)
ES (1)	ES2349043T3 (de)
IL (1)	IL181312A (de)
IS (1)	IS8609A (de)
NZ (1)	NZ553420A (de)
WO (1)	WO2006023782A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2328446T5 (es)	2000-02-04	2014-02-27	Children's Hospital Research Foundation	Uso de lipasa ácida lisosomal para tratar la aterosclerosis y enfermedades asociadas
US7442370B2 (en)	2001-02-01	2008-10-28	Biogen Idec Ma Inc.	Polymer conjugates of mutated neublastin
US7276580B2 (en)	2001-03-12	2007-10-02	Biogen Idec Ma Inc.	Neurotrophic factors
JP4571776B2 (ja) *	2002-11-05	2010-10-27	Ｊｘ日鉱日石エネルギー株式会社	潤滑油組成物
WO2004094592A2 (en)	2003-04-18	2004-11-04	Biogen Idec Ma Inc.	Polymer-conjugated glycosylated neublastin
KR101215697B1 (ko) *	2004-08-19	2012-12-28	바이오겐 아이덱 엠에이 인코포레이티드	뉴블라스틴 변형체
KR101241551B1 (ko)	2004-08-19	2013-03-11	바이오겐 아이덱 엠에이 인코포레이티드	전환 성장 인자 베타 패밀리 단백질의 리폴딩
TWI501774B (zh)	2006-02-27	2015-10-01	Biogen Idec Inc	神經性病症之治療
ES2450065T3 (es) *	2006-03-01	2014-03-21	Biogen Idec Ma Inc.	Composiciones y métodos para la administración de proteínas de la familia de ligandos del GDNF
GB0604964D0 (en)	2006-03-11	2006-04-19	Renovo Ltd	Protein folding
GB0604966D0 (en)	2006-03-11	2006-04-19	Renovo Ltd	Medicaments and proteins
GB0604938D0 (en)	2006-03-11	2006-04-19	Renovo Ltd	Proteins, nucleic acids and medicaments
JP5274795B2 (ja) *	2006-07-27	2013-08-28	三洋化成工業株式会社	タンパク質のリフォールディング方法
RU2415573C2 (ru)	2006-12-11	2011-04-10	Джапэн Сайенс Энд Текнолоджи Эйдженси	Регулятор роста растений и его применение
ES2476253T3 (es)	2007-05-01	2014-07-14	Biogen Idec Ma Inc.	P�ptidos de neublastina para su uso en el aumento de la vascularizaci�n en tejido con flujo sanguíneo deteriorado
WO2009020964A2 (en) *	2007-08-08	2009-02-12	Biogen Idec Ma Inc.	Anti-neublastin antibodies and uses thereof
JP2010132649A (ja) *	2008-10-28	2010-06-17	Sanyo Chem Ind Ltd	タンパク質のリフォールディング剤及びタンパク質の製造方法
KR101741859B1 (ko)	2009-06-22	2017-06-15	암젠 인크	화학적으로 조절된 산화환원 상태를 사용한 단백질의 재폴딩
SI3660032T1 (sl)	2009-06-25	2026-02-27	Amgen Inc.	Postopki zajemanja in čiščenja beljakovin, izraženih v nesesalskem sistemu
MX338426B (es)	2010-04-23	2016-04-15	Synageva Biopharma Corp	Enzima de enfermedad del almacenamiento lisosomico.
DK2613798T4 (en)	2010-09-09	2018-04-16	Synageva Biopharma Corp	USING LYSOSOMAL SUR LIPASE TO TREAT PATIENTS WITHOUT LYSOSOMAL SUR LIPASE
EP2675472A4 (de)	2011-02-15	2014-09-17	Synageva Biopharma Corp	Verfahren zur behandlung von mangel an lysosomaler saurer lipase
CN103987249B (zh)	2011-12-12	2015-10-21	冈山县	用于提高植物的氨基酸含量的化合物及其应用
US9556427B2 (en) *	2013-02-27	2017-01-31	Syngenta Participations Ag	Methods and compositions for preparation of nucleic acids
WO2015042580A1 (en)	2013-09-23	2015-03-26	Biogen Idec Ma Inc.	Compositions and methods for treatment of neuropathic pain
WO2016022800A1 (en)	2014-08-07	2016-02-11	Biogen Ma Inc.	Characterization of cystine knot superfamily proteins
AU2017228489A1 (en) *	2016-03-04	2018-09-06	Ngm Biopharmaceuticals, Inc.	Compositions and methods for modulating body weight
US20220340630A1 (en) *	2019-09-13	2022-10-27	National Science And Technology Development Agency	Composition of renaturation buffer solution for dimeric proteins and method of renaturation dimeric proteins using the composition thereof
CN116874555B (zh) *	2023-09-08	2023-11-28	成都华任康生物科技有限公司	一种置换液及其试剂盒和相关应用

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4352883A (en) *	1979-03-28	1982-10-05	Damon Corporation	Encapsulation of biological material
US4353888A (en) *	1980-12-23	1982-10-12	Sefton Michael V	Encapsulation of live animal cells
US4407957A (en) *	1981-03-13	1983-10-04	Damon Corporation	Reversible microencapsulation of a core material
US5525464A (en) *	1987-04-01	1996-06-11	Hyseq, Inc.	Method of sequencing by hybridization of oligonucleotide probes
US4883666A (en) *	1987-04-29	1989-11-28	Massachusetts Institute Of Technology	Controlled drug delivery system for treatment of neural disorders
US5158881A (en) *	1987-11-17	1992-10-27	Brown University Research Foundation	Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5283187A (en) *	1987-11-17	1994-02-01	Brown University Research Foundation	Cell culture-containing tubular capsule produced by co-extrusion
DE3829752A1 (de) *	1988-09-01	1990-03-22	Akzo Gmbh	Integrale asymmetrische polyaethersulfonmembran, verfahren zur herstellung und verwendung zur ultrafiltration und mikrofiltration
DE3829766A1 (de) *	1988-09-01	1990-03-22	Akzo Gmbh	Verfahren zur herstellung von membranen
US5800992A (en) *	1989-06-07	1998-09-01	Fodor; Stephen P.A.	Method of detecting nucleic acids
US5143854A (en) *	1989-06-07	1992-09-01	Affymax Technologies N.V.	Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5194596A (en) *	1989-07-27	1993-03-16	California Biotechnology Inc.	Production of vascular endothelial cell growth factor
US5350836A (en) *	1989-10-12	1994-09-27	Ohio University	Growth hormone antagonists
GB8927546D0 (en) *	1989-12-06	1990-02-07	Ciba Geigy	Process for the production of biologically active tgf-beta
US5084350A (en) *	1990-02-16	1992-01-28	The Royal Institution For The Advance Of Learning (Mcgill University)	Method for encapsulating biologically active material including cells
US5618531A (en) *	1990-10-19	1997-04-08	New York University	Method for increasing the viability of cells which are administered to the brain or spinal cord
SG47470A1 (en)	1991-04-25	1998-04-17	Univ Brown Res Found	Implantable biocompatible immunoisolatory vehicle for delivery of a selected therapeutic products
WO1993000951A1 (en) *	1991-07-02	1993-01-21	Inhale, Inc.	Method and device for delivering aerosolized medicaments
WO1993006116A1 (en)	1991-09-20	1993-04-01	Syntex-Synergen Neuroscience Joint Venture	Glial derived neurotrophic factor
US5939524A (en) *	1991-12-09	1999-08-17	The Scripps Research Institute	Platelet GPIII P1A1 and P1A2 epitopes, their preparation and use
US5414135A (en) *	1991-12-30	1995-05-09	Sterling Winthrop Inc.	Vinyl sulfone coupling of polyoxyalkylenes to proteins
US5785049A (en) *	1994-09-21	1998-07-28	Inhale Therapeutic Systems	Method and apparatus for dispersion of dry powder medicaments
ATE220327T1 (de) *	1992-09-29	2002-07-15	Inhale Therapeutic Syst	Pulmonale abgabe von aktiven fragmenten des parathormons
US6472178B1 (en)	1998-02-27	2002-10-29	Regeneron Pharmaceuticals, Inc.	Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof
US5349056A (en) *	1992-10-09	1994-09-20	Regeneron Pharmaceuticals	Modified ciliary neurotrophic factors
CA2092271C (en) *	1993-03-09	2009-10-13	Eddie Reed	Use of g-csf for treating taxol side-effects
SG48813A1 (en)	1993-08-12	1998-05-18	Cytotherapeutics Inc	Improved composition and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
DE4339605A1 (de) *	1993-11-20	1995-05-24	Beiersdorf Ag	Desodorierende Wirkstoffkombinationen auf der Basis von alpha, omega-Alkandicarbonsäuren und Fettsäurepartialglyceriden
US5834029A (en) *	1994-07-20	1998-11-10	Cytotherapeutics, Inc.	Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment
US5824784A (en)	1994-10-12	1998-10-20	Amgen Inc.	N-terminally chemically modified protein compositions and methods
US5795716A (en) *	1994-10-21	1998-08-18	Chee; Mark S.	Computer-aided visualization and analysis system for sequence evaluation
US5770577A (en) *	1994-11-14	1998-06-23	Amgen Inc.	BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US5780014A (en) *	1995-04-14	1998-07-14	Inhale Therapeutic Systems	Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5654007A (en) *	1995-06-07	1997-08-05	Inhale Therapeutic Systems	Methods and system for processing dispersible fine powders
US5739307A (en)	1995-08-28	1998-04-14	Washington University	Polynucleotide encoding neurturin neurotrophic factor
US5733729A (en) *	1995-09-14	1998-03-31	Affymetrix, Inc.	Computer-aided probability base calling for arrays of nucleic acid probes on chips
US6184200B1 (en)	1995-09-28	2001-02-06	Amgen Inc.	Truncated glial cell line-derived neurotrophic factor
US5641749A (en) *	1995-11-29	1997-06-24	Amgen Inc.	Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
US6063757A (en) *	1995-11-29	2000-05-16	Urso; Richard G.	Wound treatment method with nerve growth factor
WO1997019693A1 (en)	1995-11-29	1997-06-05	Amgen Inc.	Method for treating sensory neuropathy using glial cell line-derived neurotrophic factor (gdnf) protein product
JP4019432B2 (ja) *	1995-12-21	2007-12-12	味の素株式会社	ヒトアクチビンａのリフォールディング方法
US6299895B1 (en) *	1997-03-24	2001-10-09	Neurotech S.A.	Device and method for treating ophthalmic diseases
US6878544B2 (en)	1996-04-19	2005-04-12	Neurotech Sa	Retinal cell lines with extended life-span and their applications
US6677135B1 (en) *	1996-05-08	2004-01-13	Biogen, Inc.	Ret ligand (RetL) for stimulating neutral and renal growth
US5754524A (en) *	1996-08-30	1998-05-19	Wark; Barry J.	Computerized method and system for analysis of an electrophoresis gel test
US6083725A (en) *	1996-09-13	2000-07-04	Transkaryotic Therapies, Inc.	Tranfected human cells expressing human α-galactosidase A protein
AU736670B2 (en) *	1996-09-26	2001-08-02	Medical Research Council	Chaperone fragments
KR100195886B1 (ko) *	1996-11-01	1999-06-15	김상조	당뇨병 치료용 의약조성물
WO1998032869A1 (en)	1997-01-29	1998-07-30	Neurosearch A/S	Expression vectors and methods for in vivo expression of therapeutic polypeptides
CN1269805A (zh)	1997-07-14	2000-10-11	博尔德生物技术公司	生长激素和相关蛋白的衍生物
GB9718908D0 (en)	1997-09-05	1997-11-12	Rowett Research Services Limit	Proteins
US20020192209A1 (en)	1997-09-17	2002-12-19	Genentech, Inc.	Methods and compositions for inhibiting neoplastic cell growth
US6653098B1 (en)	1998-02-23	2003-11-25	G. D. Searle & Co.	Method of producing mouse and human endostatin
ES2262317T3 (es)	1998-03-23	2006-11-16	Genentech, Inc.	Gfr-alfa3 y sus usos.
US20020055467A1 (en)	1998-07-06	2002-05-09	Johansen Teit E.	Novel neurotrophic factors
US6593133B1 (en) *	1998-07-06	2003-07-15	Nsgene A/S	Neurotrophic factors
BR9911908A (pt) *	1998-07-06	2001-03-27	Nsgene As	ácido nucléico, sequência de ácido nucléico, processos de usar um ácido nucléico, de usar o vetor, de fabricar o polipeptìdeo, de administrar o polipeptìdeo, de tratar uma doença ou distúrbio neurodegenerativos em um animal, de determinar se uma doença ou distúrbio neurodegenerativos em um animal, de produzir qualquer um polipeptìdeo, processo para identificar, isolar ou amplificar uma sequência de ácido nucléico de neublastina, de diagnosticar ou avaliar quanto a presença de uma doença ou distúrbio ou uma predisposiçãopara desnvolvê-los, para avaliar um polipeptìdeo de neublastina purificado ou um derivado ou fragmento deste ou um modulador da atividade dos precedentes quanto a atividade em tratar ou prevenir uma doença, de tratar um distúbio neurológico, de usar a sequência de um ou mais ácidos nucléicos, e para identificar um composto candidato que induza um efeito biológico mediado pela neuroblastina, vetor, célula transformada com ácido nucléico, polipeptìdeo, cmposição, anticorpo, gene sintético, e, conjunto.
US7067473B1 (en) *	1998-07-14	2006-06-27	Janssen Pharmaceutica N.V.	Neurotrophic growth factor
DE69933771T2 (de) *	1998-07-14	2007-09-13	Janssen Pharmaceutica N.V.	Neurotrophischer wachstumsfaktor
AU771239C (en)	1998-09-14	2004-10-14	Soren Buus	A method of producing a functional immunoglobulin superfamily protein
JP2003524381A (ja)	1998-09-22	2003-08-19	ユニヴァーシティオブメリーランド，ボルチモア	システインノット成長因子ミュータント
US20020002269A1 (en)	1998-09-29	2002-01-03	Jeffrey D. Milbrandt	Artemin, a neurotrophic factor
WO2000034475A2 (en)	1998-12-09	2000-06-15	Amgen Inc.	Grnf4, a gdnf-related neurotrophic factor
ES2289630T3 (es)	1999-03-08	2008-02-01	Genentech, Inc.	Composiciones y procedimientos para el diagnostico de tumores.
US6361771B1 (en) *	1999-04-06	2002-03-26	Neurotech S.A.	ARPE-19 as a platform cell line for encapsulated cell-based delivery
MXPA01010692A (es) *	1999-04-22	2004-09-06	Univ Zuerich	Matrices de proteina modificadas para ingenieria de tejidos o liberacion controlada.
DK1185648T3 (da)	1999-06-02	2007-07-30	Genentech Inc	Fremgangsmåder og sammensætninger til inhibition af neoplastisk cellevækst
WO2001030375A2 (en) *	1999-10-29	2001-05-03	Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh	Use of gdnf for treating corneal defects
US6866851B1 (en)	1999-12-28	2005-03-15	Washington University	GFRα1-RET specific agonists and methods therefor
AU2001289307A1 (en)	2000-04-06	2001-10-23	Pharmacia Corporation	Chemically-modified myelopoietin conjugates
IL152804A0 (en)	2000-05-16	2003-06-24	Bolder Biotechnology Inc	Methods for refolding proteins containing free cysteine residues
JP2001329126A (ja)	2000-05-22	2001-11-27	Bridgestone Corp	硬化性組成物
CA2327208A1 (en) *	2000-11-30	2002-05-30	The Government Of The United States Of America	Methods of increasing distribution of therapeutic agents
IL140110A0 (en)	2000-12-05	2002-02-10	Applied Research Systems	Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
IL156559A0 (en) *	2000-12-22	2004-01-04	Genentech Inc	New use of artemin, a member of the gdnf ligand family
US7442370B2 (en)	2001-02-01	2008-10-28	Biogen Idec Ma Inc.	Polymer conjugates of mutated neublastin
TR200301208T2 (tr) *	2001-02-01	2005-05-23	Biogen, Inc.	Nublastin polimer eşlenikleri ve bunları kullanma yöntemleri.
US7276580B2 (en) *	2001-03-12	2007-10-02	Biogen Idec Ma Inc.	Neurotrophic factors
ES2374971T3 (es)	2001-03-28	2012-02-23	Biogen Idec Ma Inc.	Uso de polipéptidos de neublastina para el tratamiento del dolor neuropático.
US20040077543A1 (en) *	2001-03-28	2004-04-22	Sah Dinah W. Y.	Treatment using neublastin polypeptides
CA2740056A1 (en) *	2001-04-24	2002-11-21	Purdue Research Foundation	Methods and compositions for treating mammalian nerve tissue injuries
US7250495B2 (en) *	2001-06-20	2007-07-31	Genentech, Inc.	PRO20044 polypeptides
US20040028613A1 (en) *	2001-06-25	2004-02-12	Nastech Pharmaceutical Company Inc	Dopamine agonist formulations for enhanced central nervous system delivery
US7129085B2 (en) *	2001-10-11	2006-10-31	Bristol-Myers Squibb Company	Polynucleotides encoding a human leucine-rich repeat domain containing protein, HLLRCR-1
EP1314739A1 (de) *	2001-11-22	2003-05-28	Bayer Ag	Verfahren zur Renaturierung rekombinanter, Disulfid-enthaltender Proteine bei hohen Proteinkonzentrationen in Gegenwart von Aminen
GB0205022D0 (en) *	2002-03-04	2002-04-17	Univ Cambridge Tech	Materials and methods for the treatment of cns damage
JP4310608B2 (ja)	2002-04-25	2009-08-12	東洋紡績株式会社	Ｈｓｐ７０ファミリータンパク質基質結合ドメインフラグメントの利用方法
DE10229175A1 (de)	2002-06-28	2004-01-15	Valeo Klimasysteme Gmbh	Zylinderklappe mit strukturierter rauher Oberfläche
DE602004028801D1 (de) *	2003-01-31	2010-10-07	Biogen Idec Inc	Neublastin-mutanten
WO2004094592A2 (en)	2003-04-18	2004-11-04	Biogen Idec Ma Inc.	Polymer-conjugated glycosylated neublastin
ATE423134T1 (de)	2003-06-10	2009-03-15	Nsgene As	Verbesserte sezernierung von neublastin
US7598059B2 (en) *	2003-10-02	2009-10-06	Biogen Idec Ma Inc.	Neublastin expression constructs
ES2342397T3 (es)	2003-10-20	2010-07-06	Nsgene A/S	Vector virico para su uso en terapia genica in vivo de la enfermedad de parkinson.
WO2005072764A2 (en) *	2004-01-16	2005-08-11	Novocell, Inc.	Fibrin-bound angiogenic factors to stimulate vascularization of transplant site of encapsulated cells
US20060014288A1 (en) *	2004-06-23	2006-01-19	Tissuegene, Inc.	Nerve regeneration
US7598356B2 (en) *	2004-07-08	2009-10-06	Board of Regents of the University of Nebraska by and on behalf of the University of Nebraska Medical Center	Method for purifying a protein of the cystine-knot superfamily
KR101241551B1 (ko)	2004-08-19	2013-03-11	바이오겐 아이덱 엠에이 인코포레이티드	전환 성장 인자 베타 패밀리 단백질의 리폴딩
KR101215697B1 (ko) *	2004-08-19	2012-12-28	바이오겐 아이덱 엠에이 인코포레이티드	뉴블라스틴 변형체
US20060165667A1 (en)	2004-12-03	2006-07-27	Case Western Reserve University	Novel methods, compositions and devices for inducing neovascularization
EP1937295A2 (de) *	2005-10-11	2008-07-02	NS Gene A/S	Behandlung von retinopathien mit gfr3-agonisten
TWI501774B (zh)	2006-02-27	2015-10-01	Biogen Idec Inc	神經性病症之治療
ES2450065T3 (es) *	2006-03-01	2014-03-21	Biogen Idec Ma Inc.	Composiciones y métodos para la administración de proteínas de la familia de ligandos del GDNF
PL2019683T5 (pl) *	2006-04-25	2022-12-05	The Regents Of The University Of California	Podawanie czynników wzrostu do leczenia zaburzeń OUN
ES2476253T3 (es)	2007-05-01	2014-07-14	Biogen Idec Ma Inc.	P�ptidos de neublastina para su uso en el aumento de la vascularizaci�n en tejido con flujo sanguíneo deteriorado
WO2009020964A2 (en)	2007-08-08	2009-02-12	Biogen Idec Ma Inc.	Anti-neublastin antibodies and uses thereof

2005
- 2005-08-18 KR KR1020077005928A patent/KR101241551B1/ko not_active Expired - Fee Related
- 2005-08-18 NZ NZ553420A patent/NZ553420A/en not_active IP Right Cessation
- 2005-08-18 BR BRPI0514409-4A patent/BRPI0514409A/pt not_active Application Discontinuation
- 2005-08-18 AU AU2005277227A patent/AU2005277227B2/en not_active Ceased
- 2005-08-18 JP JP2007528062A patent/JP4959566B2/ja not_active Expired - Fee Related
- 2005-08-18 WO PCT/US2005/029638 patent/WO2006023782A2/en not_active Ceased
- 2005-08-18 CN CN200580035828XA patent/CN101043899B/zh not_active Expired - Fee Related
- 2005-08-18 EP EP05789270A patent/EP1784203B1/de not_active Expired - Lifetime
- 2005-08-18 US US11/573,771 patent/US8722862B2/en not_active Expired - Fee Related
- 2005-08-18 ES ES05789285T patent/ES2349043T3/es not_active Expired - Lifetime
- 2005-08-18 CA CA2577690A patent/CA2577690C/en not_active Expired - Fee Related
- 2005-08-18 DE DE602005022082T patent/DE602005022082D1/de not_active Expired - Lifetime
- 2005-08-18 AT AT05789270T patent/ATE472333T1/de not_active IP Right Cessation
- 2005-08-18 CN CN2005800359225A patent/CN101123978B/zh not_active Expired - Fee Related
2007
- 2007-02-13 IL IL181312A patent/IL181312A/en not_active IP Right Cessation
- 2007-02-14 IS IS8609A patent/IS8609A/is unknown
2014
- 2014-03-26 US US14/226,481 patent/US8969042B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US8969042B2 (en)	2015-03-03
BRPI0514409A (pt)	2008-06-10
US20080249287A1 (en)	2008-10-09
US8722862B2 (en)	2014-05-13
JP2008510720A (ja)	2008-04-10
EP1784203A4 (de)	2008-08-20
WO2006023782A2 (en)	2006-03-02
CN101123978A (zh)	2008-02-13
JP4959566B2 (ja)	2012-06-27
ES2349043T3 (es)	2010-12-22
HK1103988A1 (en)	2008-01-04
CA2577690C (en)	2013-08-06
IL181312A (en)	2013-12-31
CA2577690A1 (en)	2006-03-02
IS8609A (is)	2007-02-14
CN101123978B (zh)	2012-12-12
EP1784203A2 (de)	2007-05-16
US20140322752A1 (en)	2014-10-30
WO2006023782A3 (en)	2007-01-04
KR101241551B1 (ko)	2013-03-11
DE602005022082D1 (de)	2010-08-12
AU2005277227B2 (en)	2011-10-06
KR20070050965A (ko)	2007-05-16
EP1784203B1 (de)	2010-06-30
AU2005277227A1 (en)	2006-03-02
CN101043899A (zh)	2007-09-26
IL181312A0 (en)	2007-07-04
NZ553420A (en)	2010-02-26
CN101043899B (zh)	2011-03-30

Legal Events

Date	Code	Title	Description
2010-12-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
IL181312A0 (en)	2007-07-04	Refolding transforming growth factor beta family proteins
ECSP056111A (es)	2006-03-01	Derivados de 2-acilamino-4-feniltiazol, su preparación y aplicación en terapeutica
MXPA06000921A (es)	2006-03-30	Derivados de benzamidazoles como inhibidores de mek.
TN2011000229A1 (en)	2012-12-17	Antibody formulation
CY1108077T1 (el)	2014-02-12	Αρυλο-υποκατεστημενες πολυκυκλικες αμινες, μεθοδος για την παρασκευη τους και η χρηση τους ως φαρμακων
WO2003084922A8 (de)	2005-01-13	Acyl-4-carboxy-phenyl-harnstoffderivate, verfahren zu deren herstellung und deren verwendung
CY1116506T1 (el)	2017-03-15	Αντισωματα εναντι masp-2
CY1110780T1 (el)	2015-06-10	Τοπικα σκευασματα νεπαφενακης
BRPI0417684A (pt)	2007-03-20	composto, composição farmacêutica, e, uso de um composto
JO3449B1 (ar)	2020-07-05	صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
SG140591A1 (en)	2008-03-28	Heterocycle-substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
EP2441838A3 (de)	2013-07-10	Fusionsproteine mit natürlichen Verbindungen
CY1110926T1 (el)	2015-06-10	Υποκατεστημενες πυραζολο πυριδινες, συνθεσεις που τις περιεχουν, διαδικασια παρασκευης και χρηση
DK2027152T3 (da)	2012-02-20	Peptidfragmenter til induktion af syntese af ekstracellulære matrixproteiner
DE60327651D1 (de)	2009-06-25	Thio-analoga von paclitaxel und deren vorprodukte
BR0211761A (pt)	2007-01-09	depsipeptìdeos e processos para preparar os mesmos
DK1240326T3 (da)	2009-06-02	Udlösende receptor der er involveret i naturlig cytotoxicitet medieret af humane naturlige dræberceller og antistoffer som identificerer denne receptor
BRPI0406037A (pt)	2005-08-23	Produto de carne ou análogo de carne contendo soja, e, método para preparar o mesmo
IL165558A0 (en)	2006-01-15	N-benzoylureidocinnamate derivatives method for production and use thereof
ATE316101T1 (de)	2006-02-15	Thrombinspaltbare faktor-x-analoga
DE60102147D1 (de)	2004-04-01	Anti-gefrier proteine, deren herstellung und verwendung
DE602006006046D1 (de)	2009-05-14	Verwendung nativer peptide und deren optimierter derivate zur impfung
WO2007104934A3 (en)	2008-01-03	Protein folding
ATE479688T1 (de)	2010-09-15	Herstellung von famciclovir und anderen purinderivaten
UY29040A1 (es)	2006-02-24	Procedimiento de amino-tropano, su preparación y aplicación en terapéutica